Vor Biopharma shareholders OK share increase to 800M, re-elect directors

Vor Biopharma Inc.

Authorized common shares increased from 400M to 800M; approved by 65.5M votes for vs 7.7M against.
Class I directors Matthew Patterson and Daniella Beckman re-elected with ~53.4M and ~52.7M votes for.
Ernst & Young LLP ratified as independent auditor for FY2025 with 73.1M votes for.
Annual meeting had 73.2M shares represented, ~58.7% of outstanding.

item 5.03 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Vor Biopharma Inc.: Increased authorized common stock from 400,000,000 to 800,000,000 shares (effective 2025-05-22).

Change: charter amendment
Effective: 2025-05-22

Exact text from the filing

On May 22, 2025, Vor Biopharma Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock (“Common Stock”) from 400,000,000 to 800,000,000.

View on SEC.gov

102 governance changes filed in the last 30 days. Browse all governance changes →

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-125833

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.